Covidien, McDermott Unit Partner on Radioisotope

The companies are staying mum on the figures.

Medical device maker Covidien Ltd. has said it signed a development agreement with a subsidiary unit of McDermott International Inc.

Under the deal, Covidien, which would not reveal the amount of the deal, and Babcock & Wilcox Technical Services Group Inc. will create technology to make a radioisotope used for molecular imaging and medical procedures. The companies will zero in on molybdenum-99, the parent isotope of technetium-99m, the most widely used radioisotope for molecular imaging and nuclear medicine procedures.

The company said in a statemet the United States currently imports 100 percent of its molybdenum-99, which is made at a handful of aging reactors and can be affected by unplanned shutdowns.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters